Segment Information Segment Information (Tables)

12 Months Ended

Dec. 31, 2013

Segment Reporting [Abstract]

Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]

	2013			2012			2011
Segment revenue—to unaffiliated customers:
Human pharmaceutical products:
Endocrinology	$	7,304.4		$	6,810.9		$	6,806.7
Neuroscience	7,216.2			7,575.1			9,723.8
Oncology	3,268.5			3,281.6			3,322.2
Cardiovascular	2,923.2			2,632.5			2,486.4
Other pharmaceuticals	249.3			266.8			268.8
Total human pharmaceutical products	20,961.6			20,566.9			22,607.9
Animal health	2,151.5			2,036.5			1,678.6
Total segment revenue	$	23,113.1		$	22,603.4		$	24,286.5
Segment profits(1):
Human pharmaceutical products	$	5,015.0		$	4,393.4		$	5,837.9
Animal health	556.6			508.1			301.0
Total segment profits	$	5,571.6		$	4,901.5		$	6,138.9
Reconciliation of total segment profits to consolidated income before taxes:
Segment profits	$	5,571.6		$	4,901.5		$	6,138.9
Other profits (losses):
Income related to termination of the exenatide collaboration with Amylin (Note 4)	495.4			787.8			—
Acquired in-process research and development (Notes 3 and 4)	(57.1		)	—			(388.0		)
Asset impairment, restructuring, and other special charges (Note 5)	(120.6		)	(281.1		)	(401.4		)
Total consolidated income before taxes	$	5,889.3		$	5,408.2		$	5,349.5

Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]

	2013		2012		2011
Geographic Information
Revenue—to unaffiliated customers(1):
United States	$	12,889.7	$	12,313.1	$	12,977.2
Europe	4,338.4		4,259.7		5,290.9
Japan	2,063.8		2,246.2		2,104.1
Other foreign countries	3,821.2		3,784.4		3,914.3
Revenue	$	23,113.1	$	22,603.4	$	24,286.5
Long-lived assets(2):
United States	$	4,649.6	$	5,064.7	$	5,485.3
Europe	2,469.7		2,281.1		2,220.2
Japan	81.1		101.5		102.9
Other foreign countries	1,540.9		1,543.2		1,564.0
Long-lived assets	$	8,741.3	$	8,990.5	$	9,372.4